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Introduction 
 
 Genetic testing has opened new doors into understanding a patient’s future health. 
The human genome is extremely vast and complicated. Testing an entire genome for the 
innumerable genetic variants that have a bearing on the development of cancer is costly 
both in time25 and efficiency. Testing for just a single gene results in seeing a whole group 
of variations, which may or may not be pathogenic11. Pathogenic, in this case, is defined 
as a variant known to cause or increase risk of a disease, the degree of which is determined 
by how co-segregated it is with the disease16,17. One of the genes that is examined when 
looking at hereditary diffuse gastric cancer (HDGC) often is Cadherin-1, or CDH1. 
The human CDH1 gene codes for epithelial cadherin, or E-cadherin. The E-
cadherin family are transmembrane proteins involved in signaling pathways within the cell, 
cell maturation, cell movement, and cellular adhesion in the epithelial tissue in many 
organs. Due to the protein’s functions, the CHD1 gene is classified as a tumor suppressor 
gene, meaning it prevents cells from undergoing unregulated rapid division, which results 
in tumor formation. In the case of CDH1, the formation of tumors is usually the result of 
the loss of contact inhibition. A variation in either the gene or a regulatory factor, such as 
micro RNA32, can result in a change of the gene’s expression, resulting in the absence or 
truncation of a protein. When the gene that codes for E-cadherin contains a pathogenic 
variant, researchers have found associations in genotype with an increased risk of lobular 
breast cancers in females15 and hereditary diffuse gastric cancer in both sexes34. Cancer is 
a multigenic disease14, meaning it requires multiple genetic abnormalities to occur. This is 
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why a variant does not guarantee that an individual will develop cancer, only increasing 
the likelihood of it developing.  
The CDH1 gene is located on chromosome 16 and contains just over 98,000 base 
pairs19. Each active region in a gene codes for amino acids that are used to build proteins 
that have specific functions in the body10. Being able to distinguish variants in these regions 
can show us how the protein is altered and the result of a modification. From that 
information, a variant can be classified as pathogenic or not. With such a large number of 
base pairs and variants in each, the question becomes, which regions of the CDH1 gene are 
clinically relevant? 
Architecture of CDH1 
The CDH1 gene is made up of five distinct regions5,33 (Figure 2). Each region plays 
a different role in how E-cadherin is formed. The first region codes for the signaling peptide 
that E-cadherin 1 uses as a part of pathways involving contact inhibition through adherens 
junctions8. This region is comprised of exon one and partially exon two, and it is the second 
smallest region.  
The next region of CDH1 is the precursor region. It is comprised of the remaining 
portion of exon two, exon three, and part of four. The coding in this region is responsible 
for building the precursor protein for E-cadherin. This precursor will remain inactive until 
it has undergone cleavage and other posttranscriptional modifications26. It remains inactive 
due to the risk of detrimental morphogenesis9 of the tissue due to overabundant E-cadherin. 
Changes in this region can result in the precursor being truncated, incorrectly cleaved, or 
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absent26. These changes would result in E-cadherin being unable to adhere and form 
adherens junctions with other cells’ E-cadherins.  
The largest region of CDH1 is the extracellular domain. It is made up of the latter 
portion of exon four and exons five through thirteen. The extracellular domain of the E-
cadherin protein lies outside of the cell to interact with the extracellular domains of other 
cells’ E-cadherin to adhere to each other and form adheren junctions8. The Ca2+ pockets 
that mediate e-cadherin’s adhesion are highly conserved28, meaning that mutations to this 
region are very detrimental. Changes to this region would result in a change in E-cadherin 
adhesive abilities and impaired contact inhibition of the cells. If cellular adhesion is lost, 
the cancer cells are more likely to undergo metastasis due to their new ability to easily 
break off from one another. 
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Figure 1. Ribbon structure of two E-cadherin extracellular domains interacting with 
each other, mediated by calcium ions27. 
Following the extracellular domain is the transmembrane region. It is the shortest 
region, being only comprised of parts of exons thirteen and fourteen. This region is 
responsible for connecting the extracellular domain of the E-cadherin protein with the 
cytoplasmic region across a cell’s membrane. Any changes to this region will inhibit the 
structure’s ability to hold the extracellular domain and cytoplasmic regions together, thus 
not allowing e-cadherin to be attached to the cell or actin cytoskeleton. Given its size, role 
in adherens junctions and highly conserved nature, it is expected this region will contain 
the most pathogenic variants. 
 
Figure 2. Illustration of the extracellular domain forming an adheren junction (AJ) 
with another E-cadherin 1, and the cytoplasmic anchor binding α-catenin (green square) 
to attach to the actin cytoskeleton and the binding of β-catenin (blue circle) to the 
cytoplasmic anchor28. 
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The final region of CDH1 is the E-cadherin cytoplasmic domain that anchors the 
cadherin to the parent cell through association with the actin cytoskeleton via binding to α-
catenin. The cytoplasmic region is also responsible for binding β-catenin. It is comprised 
of the remaining exons, 14 through 16. Variations in this region can result in it being 
truncated and reduce its ability to anchor the protein to the cell’s cytoskeleton. These 
variants may also cause more β-catenin to be released and enter the nucleus causing a 
transactivation of genes associated with cellular division, such as Myc. 
 
 Figure 3. Functional regions of the CDH1 gene and the exons that are contained in 
each5. Figure is not made to scale. 
Clinical Relevance of CDH1 
Variations in CDH1 are known to be associated with increased risks for gastric 
cancers and lobular breast cancers for years33. In a 2015 study by Wei Zeng, et al., the 
researchers confirmed that CDH1 had clinicopathological significance. This conclusion 
was reached by studying methylation levels of CDH1 in cancerous and non-cancerous 
cells. Cancerous cells had significantly higher hypermethylation levels, meaning more of 
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the gene was inactivated, resulting in an interference in E-cadherin 1’s functions36. Cells 
whose cadherins were not functioning properly exhibited malignancy.  
Variants in CDH1 are considered autosomal dominant due to the fact only one copy 
of the variant is needed to be pathogenic. Heterozygosity is rarely lost. The downregulation 
of the second, normal allele is thought to be caused by hypermethylation of that allele29. 
Downregulation of E-cadherin is also seen in malignant cells when the epithelial growth 
factor receptor, to which E-cadherin is coupled14, is stimulated by epithelial growth factor 
or TGF-α4. 
E-cadherin 1 is also seen to inhibit many proteins involved DNA replication and 
cell proliferation, such as Geminin and Cdc631. The loss of E-cadherin 1 would result in a 
loss of inhibition of these proteins, causing the cell to have an increased rate of division. 
Importance of Truncation 
Protein truncation has been widely documented in proteogenomic studies in cancer 
in a wide variety of proteins. Truncating a protein means to shorten a protein by removing 
amino acids starting at either end. While studying TP53, another tumor suppressor, Marlon 
Lindenbergh-van der Plas et al., suggested that truncation can be used as a strong 
prognosticator for determining if a variant is pathogenic or not18.  
Demographics 
Gastric cancers are the third leading cause of cancer-related deaths worldwide. 
Two-thirds of these come from eastern Asia, eastern Europe, and South America. The case 
fatality rate in these regions is very high at 78% and only drops slightly to 65% in the 
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industrialized world. This distribution may be attributed to H. pylori, a causative agent of 
cancer30.  
Difference Between Hereditary Diffuse Gastric Cancer and Familial Diffuse 
Gastric Cancer  
Familial diffuse gastric cancer (FDGC) is extremely similar to HDGC. The main 
difference between the two is that HDGC is purely genetic. The development of FDGC is 
dependent on both environmental and genetic factors6. It is included in this study due to its 
relation to HDGC and its genetic component. 
 
Methods 
 Genetic variants of the CHD1 gene were gathered from the ClinVar database. They 
were filtered by looking for variants in CDH1 associated with HDGC or FDGC and labeled 
as pathogenic, likely pathogenic, or conflicting. In addition to looking at the literature, the 
number of submissions, most recent submission, and summaries given were examined. 
Many submissions from Ambry Genetics lacked literature, but they gave a detailed chart2 
of their criteria for determining if a variant was pathogenic.  
 When I read the literature, I focused on looking for two main criteria. First, the 
variant had to be present in multiple generations12. In the generations where the variant was 
present, individuals diagnosed with HDGC must have been about age 50 or below35. Once 
an individual has reached the age of 50, the chances of developing gastric cancer due to a 
genetic cause decreases1. This means the cause of cancer would be more likely arise from 
a somatic mutation or DNA damage once an individual has reached age 50. One factor that 
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strengthened my determination of pathogenicity was if multiple individuals within a 
generation were diagnosed with gastric cancer3. Once these factors were evaluated, how 
the variant affected CDH1 and its product was examined.  
 Once the variants were determined to be pathogenic, their location in terms of exon 
or intron was noted. If the exon or intron location was not present in the literature, the 
variants’ base location on chromosome 16 was input into the UCSC Genome Browser and 
their locations were determined from there.  
Non-pathogenic Variants 
 Not all of the variants listed by ClinVar are expected to be pathogenic. Variants 
that have only been seen in a single individual were designated as non-pathogenic in terms 
of HDGC because it is unknown if the variant is hereditary. If a variant on the list was not 
directly listed as being associated with HDGC or FDGC, it was also marked as non-
pathogenic due to it being more strongly associated with lobular breast cancer or not 
directly related to HDGC at all. A variant that was also not strongly segregated with HDGC 
was also marked as non-pathogenic. It has been seen in multiple unrelated individuals and 
affects protein function and mRNA splicing, but its correlation to cancer is weak23. 
 Example of Pathogenic Variant 
 The variant, NM_004360.4(CDH1):c.1003C>T (p.Arg335Ter), has been identified 
as pathogenic by multiple submitters on ClinVar. This variant results in a change from 
cytosine to thymine at coding locus 1003, which results in a change from Arginine to a 
premature stop codon (Ter) at codon 335. This will result in loss of E-cadherin function 
due to either protein truncation or nonsense-mediated mRNA decay21. 
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Results 
 Of the 68 variants listed by the ClinVar database, 51 variants were deemed as 
pathogenic (Figure 3). Exons contained more pathogenic variations with 41, and introns 
only had 10 variants. Exon size did not play a role in the number of pathogenic variants 
they contained. This is shown by the largest exon, 16, containing only one pathogenic 
variant, while the shortest exon, 2, had seven pathogenic variants. Exon 5 contained no 
reported pathogenic variants. Most pathogenic variants were reported or suggested to 
truncate E-cadherin 1. 
 By region, the extracellular domain contained the most pathogenic variants, with 
a total of approximately 30 variants from both exons and introns. The signaling and 
precursor regions both contain approximately eight pathogenic variants each. The 
transmembrane region contains approximately seven pathogenic regions. The 
cytoplasmic anchoring region only contains about four pathogenic variants.  
 
Figure 4. Scaled diagram of the CDH1 gene by exon. The introns are not to scale due to 
their immense size in comparison to the exons. The number of pathogenic variants for 
exons are listed below the gene and the pathogenic variants for the intron are listed above 
the gene.  
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Importance of intron variants 
 Introns do not code for a protein; however, they play an important role in splicing. 
Variants in these regions alter splice donor sites.  This can cause either an abnormal 
protein produced, or nonsense-mediated mRNA decay to occur22.  
Mass Deletions 
 Mass deletions were omitted from my results. Cancers resulting from mass 
deletions may be due to the deletions affecting other genes and cannot be solely attributed 
to the deletion in CDH1 resulting in the cancer. Therefore, the deletion itself may be 
clinically relevant, but just not solely in terms of CDH1. An example of this is seen in 
variant nsv513771 where exons 1 and 2 were deleted, but so was the entire CDH3 
gene24,25 which is involved in loss of heterozygosity events associated with several 
cancers that CDH1 is associated with7.  
 
Discussion 
 As expected, the extracellular domain contained the most pathogenic variants. 
Containing over half of the pathogenic variants suggest that the extracellular region of the 
CDH1 is sensitive to changes in amino acid sequence. The same can be inferred about exon 
2 of the gene given that it contains the most variants out of the individual exons. The coding 
sequences for the end of the signaling region to the beginning of the precursor region would 
be sensitive to changes in their amino acid sequences as well.   
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Clinical Use 
 As direct-to-consumer (DTC) genetic testing has become more accessible, the 
legality of the “diagnosis” an individual can perceive from their results has been called into 
question. Currently, genetic testing companies are not legally allowed to provide medical 
advice with the raw data collected from the results of the individual20. It is up to a medical 
professional to interpret these results.  
The field of genetic testing is relatively new in the clinical world and not all medical 
professionals are well versed in interpreting genetic results. Studies like mine can aid 
doctors in diagnosing patients with genetic conditions and diseases by providing them with 
a map of which areas are sensitive to variation. 
Limitations 
 The variants in this study were drawn from an expansive, but singular database. It 
relies on submissions to compile the variants. Variants included in literature outside the 
database were not able to be included as a result.  
 Further Research 
 Research into literature outside the database could greatly expand the content of 
this list as well as improve its accuracy. Encouraging submissions to databases like ClinVar 
would immensely streamline research in the future. One step further would be to 
consolidate all data into a singular database.  
 Ambry Genetics only provided results of clinical data, so research into any 
submissions without literature would strength the position on if the variants are pathogenic 
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or not. Any variant with a single submitter would benefit from having more submissions, 
re-evaluating their conclusions.  
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